NICE has updated its guidance for polyendocrine metabolic ovarian syndrome, or PMOS, recommending annual reviews as part of a broader push to improve diagnosis, monitoring and ongoing care for people living with the condition. The draft guidance, published on 1 July 2026, is open for consultation until 11 August 2026 and is expected to be finalised in December 2026. ([nice.org.uk](https://www.nice.org.uk/news/articles/nice-recommends-annual-review-for-pmos-in-new-draft-guideline-aimed-at-improving-diagnosis-and-care?utm_source=openai))
What the draft guidance says
The new draft sets out recommendations aimed at improving consistency of care and supporting earlier diagnosis and management. NICE said the proposed annual review is intended to help clinicians identify changing symptoms sooner and provide more regular follow-up for patients affected by PMOS. ([nice.org.uk](https://www.nice.org.uk/news/articles/nice-recommends-annual-review-for-pmos-in-new-draft-guideline-aimed-at-improving-diagnosis-and-care?utm_source=openai))
According to NICE, PMOS is a common but often overlooked condition that can have a major impact on health and wellbeing. The draft guidance also includes treatment recommendations to address the underlying causes of hirsutism, while stopping short of recommending mechanical laser and light therapies for hair reduction because they are not considered cost-effective for improving overall health and wellbeing. ([nice.org.uk](https://www.nice.org.uk/news/articles/nice-recommends-annual-review-for-pmos-in-new-draft-guideline-aimed-at-improving-diagnosis-and-care?utm_source=openai))
Why the update matters for patients
The consultation is designed to gather feedback from healthcare professionals, patients and the public before the guidance is finalised. NICE estimates that recommending laser and light therapies would have a cost impact of up to £100 million per year in England, underlining the financial implications of treatment decisions alongside the clinical debate. ([nice.org.uk](https://www.nice.org.uk/news/articles/nice-recommends-annual-review-for-pmos-in-new-draft-guideline-aimed-at-improving-diagnosis-and-care?utm_source=openai))
For patients, the proposed annual review could mean more structured follow-up and a clearer route to assessment if symptoms change over time. For clinicians, the draft aims to standardise management and reduce variation in care across services. NICE expects the final guideline to be published in December 2026. ([nice.org.uk](https://www.nice.org.uk/news/articles/nice-recommends-annual-review-for-pmos-in-new-draft-guideline-aimed-at-improving-diagnosis-and-care?utm_source=openai))
The consultation is now open, and the outcome will determine whether the annual review recommendation and the wider treatment framework become part of routine NHS practice later this year. ([nice.org.uk](https://www.nice.org.uk/news/articles/nice-recommends-annual-review-for-pmos-in-new-draft-guideline-aimed-at-improving-diagnosis-and-care?utm_source=openai))
